Qube Research Discloses 1% Stake in Bakkavor Group PLC
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 hour ago0mins
- Stake Disclosure: Qube Research & Technologies Limited disclosed a holding of 5,683,128 cash-settled derivatives in Bakkavor Group PLC, representing 0.98% of the relevant securities, indicating its investment interest in the company.
- Trading Information: In recent dealings, Qube reduced its long position in Bakkavor by selling 2,036 and 2,162 shares at prices of £227.50 and £28.00 respectively, reflecting its response to market dynamics.
- Compliance Requirements: This disclosure adheres to Rule 8 of the Takeover Code, ensuring transparency and maintaining market fairness, highlighting Qube's commitment to compliance.
- Market Impact: Qube's stake disclosure may influence Bakkavor's market performance, prompting investors to monitor subsequent stock price fluctuations and market reactions.
BAK.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BAK
Wall Street analysts forecast BAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAK is 3.30 USD with a low forecast of 2.80 USD and a high forecast of 3.80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
0 Buy
2 Hold
1 Sell
Moderate Sell
Current: 2.940
Low
2.80
Averages
3.30
High
3.80
Current: 2.940
Low
2.80
Averages
3.30
High
3.80
Grupo Santander
Neutral -> Underperform
downgrade
$2.80
2025-10-15
Reason
Grupo Santander
Price Target
$2.80
2025-10-15
downgrade
Neutral -> Underperform
Reason
Grupo Santander downgraded Braskem to Underperform from Neutral with a $2.80 price target.
UBS
Buy -> Neutral
downgrade
2025-09-26
Reason
UBS
Price Target
2025-09-26
downgrade
Buy -> Neutral
Reason
UBS downgraded Braskem to Neutral from Buy with a price target of $3.80, down from $5.10. The firm sees a tough backdrop for spreads, including a deterioration in the short-term outlook. UBS is more conservative on shares of Braskem as it sees no easy path to ceasing its cash consumption without a potential asset sale.
JPMorgan
Neutral
downgrade
$6 -> $5
2025-08-27
Reason
JPMorgan
Price Target
$6 -> $5
2025-08-27
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Braskem to $5 from $6 and keeps a Neutral rating on the shares.
Bradesco BBI
Outperform -> Neutral
downgrade
$4
2025-05-11
Reason
Bradesco BBI
Price Target
$4
2025-05-11
downgrade
Outperform -> Neutral
Reason
Bradesco BBI downgraded Braskem to Neutral from Outperform with a $4 price target.
See All Ratings
About BAK
Braskem SA is a Brazil-based integrated petrochemical company for the first and second generation of thermoplastic resins. The Company's activities are divided into three operational segments: Brazil; the United States and Europe; and Mexico. The Brazil segment is focused on the production of polyethylene (PE), polypropylene (PP) and polyvinylchloride (PVC) resins, in addition to basic chemical inputs such as ethylene, propylene, butadiene, benzene, toluene, chlorine, soda, and solvents, among others. The United States and Europe segment is responsible for the production of polypropylene in units in the United States and Germany. The Mexico segment consists of the operation of ethylene cracker and polyethylene units located in Mexico.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What does Qube Research's 1% stake in Bakkavor Group represent?
How does Rule 8 of the Takeover Code ensure market transparency?
How might Qube's stake disclosure affect Bakkavor's stock price in the future?
Will Qube Research further reduce its position in Bakkavor Group soon?